T. Ross

A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma

S. Wingert, A. M. Ovacik, D. E. de Almeida Nagata, 2022, Leukemia.

Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity

J. Koch, S. Wingert, M. Tesar, 2019, mAbs.

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

J. Koch, S. Wingert, M. Tesar, 2018, Blood.

The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML

D. Nowak, W. Hofmann, J. Endell, 2022, Blood.